Claims for Patent: 8,895,010

Summary for Patent: 8,895,010

Title:	Antibody polypeptides that antagonize CD40L
Abstract:	Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V.sub.H or V.sub.K domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
Inventor(s):	Nadler; Steven G. (Princeton, NJ), Tamura; James K. (Yardley, PA), Price; Laura (Langhorne, PA), Rehfuss; Robert P. (North Wales, PA), Suchard; Suzanne J. (Wilmington, DE), Suri; Anish (Yardley, PA), Bryson; James William (Langhorne, PA), Yamniuk; Aaron (Lawrenceville, NJ), Grant; Steven (Swaffham Prior, GB), Ignatovich; Olga (Cambridge, GB), Drew; Philip (Histon, GB)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ) Domantis Limited (Brentford, Middlesex, GB)
Application Number:	13/650,493
Patent Claims:	1. An isolated antibody polypeptide comprising a first variable domain that specifically binds human CD40L, wherein CD40L comprises the amino acid sequence of SEQ ID NO: 1, wherein the amino acid sequence of the first variable domain comprises (a) a CDR1 region of BMS2h-572-633 comprising SEQ ID NO: 2, (b) a CDR2 region of BMS2h-572-633 comprising SEQ ID NO: 3, (c) a CDR3 region of BMS2h-572-633 comprising SEQ ID NO: 4, (d) a FR1 region of BMS2h-572-633 comprising SEQ ID NO: 5, (e) a FR2 region of BMS2h-572-633 comprising SEQ ID NO: 6, (f) a FR3 region of BMS2h-572-633 comprising SEQ ID NO: 7, and (g) a FR4 region of BMS2h-572-633 comprising SEQ ID NO: 8; and wherein the antibody polypeptide inhibits binding of CD40L to CD40 with an EC50 of 100 pM to 100 nM. 2. The antibody polypeptide of claim 1, wherein the antibody polypeptide is selected from the lineage group of BMS2h-572, and wherein the amino acid sequence of the first variable domain further comprises: (a) a CDR1 region having a sequence Trp-X.sub.1-Leu-Met-Gly (SEQ ID NO: 2), wherein X.sub.1 is Glu; (b) a CDR2 region having a sequence Gly-Ile-Glu-Gly-Pro-Gly-Asp-Val-Thr-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly (SEQ ID NO: 3); and (c) a CDR3 region having a sequence Lys-X.sub.2-Y.sub.2- Z.sub.2-Ser-Asp-Tyr (SEQ ID NO: 4), wherein X.sub.2 is Asp, Y.sub.2 is Ala, and Z.sub.2 is Lys. 3. The antibody polypeptide of claim 2, wherein the amino acid sequence of the first variable domain further comprises: (a) a FR1 region having a sequence Glu-Val-Gln-Leu-Leu-Glu-Ser-Gly-Gly-Gly-Leu-Val-Gln-Pro-Gly-Gly-- Ser-Leu-Arg-Leu-Ser-Cys-Ala-Ala-Ser-Gly-Phe-Thr-Phe-Asn (SEQ ID NO: 5); (b) a FR2 region having a sequence Trp-X.sub.1-Arg-Gln-Ala-Pro-Gly-Lys-Gly-Leu-Glu-Trp-Val-Ser (SEQ ID NO: 6), wherein X.sub.1 is Ala; (c) a FR3 region having a sequence Arg-Thr-Phe-Ile-Ser-Arg-Asp-Asn-Ser-Lys-Asn-Thr-Leu-Tyr-Leu-Gln-Met-Asn-S- er-Leu-Arg-Ala-Glu-Asp-Thr-Ala-Val-Tyr-Tyr-Cys-Val-Lys-Val-Gly (SEQ ID NO: 7); and (d) a FR4 region having a sequence Arg-Gly-Gln-Gly-Thr-Leu-Val-Thr-Val-Ser-Ser (SEQ ID NO: 8). 4. An antibody polypeptide comprising the amino acid sequence of BMS2h-572-633 (SEQ ID NO: 274). 5. The antibody polypeptide of claim 1, wherein the antibody polypeptide is a domain antibody (dAb). 6. The antibody polypeptide of claim 4, wherein the antibody polypeptide is a fusion polypeptide comprising the first variable domain and an Fc domain. 7. The fusion polypeptide of claim 6, wherein the fusion polypeptide comprises an IgG4 Fc domain. 8. The fusion polypeptide of claim 6, wherein the fusion polypeptide comprises an IgG1 Fc domain. 9. The fusion polypeptide of claim 6, wherein the fusion polypeptide comprises a CT-Long domain. 10. The fusion polypeptide of claim 6, wherein the fusion polypeptide comprises a CT-short domain. 11. The fusion polypeptide of claim 6, wherein the fusion polypeptide comprises a N297Q Long Fc domain. 12. The fusion polypeptide of claim 6, wherein the fusion polypeptide comprises a N297Q Short Fc domain. 13. The antibody polypeptide of claim 1, wherein the antibody polypeptide further comprises a second variable domain that specifically binds a second antigen, wherein the second antigen is an antigen other than human CD40L. 14. The antibody polypeptide of claim 13, wherein the second antigen is a cluster of differentiation (CD) molecule or a Major Histocompatibility Complex (MHC) Class II molecule. 15. The antibody polypeptide of claim 13, wherein the second antigen is serum albumin (SA). 16. A pharmaceutical composition comprising a therapeutically-effective amount of the antibody polypeptide of claim 1 and a pharmaceutically acceptable carrier. 17. The pharmaceutical composition of claim 16, further comprising an immunosuppressive/immunomodulatory and/or anti-inflammatory agent. 18. A method of antagonizing CD40L activity in a patient with an immune disease in need of such treatment, comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition of claim 16 to antagonize CD40L activity in the patient. 19. The method of claim 18, wherein the isolated antibody polypeptide is administered in combination with an immunosuppressive/immunomodulatory and/or inflammatory agent. 20. The method of claim 18, wherein the immune disease is an autoimmune disease or a graft-related disease. 21. The method of claim 18, wherein the immune disease is a graft-related disease. 22. The method of claim 21, wherein the graft-related disease comprises solid organ, tissue and/or cell transplant rejection. 23. The method of claim 21, wherein the graft-related disease is graft versus host disease (GVHD). 24. The method of claim 21, wherein the graft-related disease is an acute transplant rejection. 25. The method of claim 21, wherein the graft-related disease is a chronic transplant rejection. 26. The method of claim 21, wherein the isolated antibody polypeptide is co-administered with a CTLA4 mutant molecule. 27. The method of claim 26, wherein the CTLA4 mutant molecule is L104EA29Y-Ig (belatacept). 28. The method of claim 18, wherein the immune disease is selected from the group consisting of Addison's disease, allergies, ankylosing spondylitis, asthma, atherosclerosis, autoimmune diseases of the ear, autoimmune diseases of the eye, autoimmune hepatitis, autoimmune parotitis, colitis, coronary heart disease, Crohn's disease, diabetes, including Type 1 and/or Type 2 diabetes, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel disease, immune response to recombinant drug products, systemic lupus erythematosus, male infertility, multiple sclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathies, thyroiditis, transplant rejection, vasculitis, AIDS, atopic allergy, bronchial asthma, eczema, leprosy, schizophrenia, inherited depression, chronic fatigue syndrome, Alzheimer's disease, Parkinson's disease, myocardial infarction, stroke, autism, epilepsy, Arthus's phenomenon, anaphylaxis, alcohol addiction, and drug addiction. 29. The method of claim 18, wherein the immune disease is selected from the group consisting of myasthenia gravis, idiopathic thrombocytopenic purpura, and systemic sclerosis. 30. An isolated antibody polypeptide comprising a first variable domain of BMS2h-572 (SEQ ID NO: 223). 31. An isolated antibody polypeptide comprising a first variable domain selected from the group consisting of the amino acid sequence of BMS2h-572-6 (SEQ ID NO: 243), BMS2h-572-608 (SEQ ID NO: 251), BMS2h-572-614 (SEQ ID NO: 257), BMS2h-572-619 (SEQ ID NO: 262), BMS2h-572-633 (SEQ ID NO: 274), BMS2h-572-634 (SEQ ID NO: 275), or BMS2h-572-635 (SEQ ID NO: 276). 32. A fusion polypeptide comprising SEQ ID NO: 1355. 33. A pharmaceutical composition comprising a therapeutically-effective amount of the antibody polypeptide of claim 4 and a pharmaceutically acceptable carrier. 34. A pharmaceutical composition comprising a therapeutically-effective amount of the antibody polypeptide of claim 6 and a pharmaceutically acceptable carrier. 35. A pharmaceutical composition comprising a therapeutically-effective amount of the antibody polypeptide of claim 31 and a pharmaceutically acceptable carrier. 36. A pharmaceutical composition comprising a therapeutically-effective amount of the fusion polypeptide of claim 32 and a pharmaceutically acceptable carrier.

Details for Patent 8,895,010

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	NULOJIX	belatacept	For Injection	125288	06/15/2011		2031-10-13